Skip to main content
    S

    Sabra Healthcare REIT Inc (SBRA)

    Official site

    REAL ESTATE • REIT - HEALTHCARE FACILITIES • NASDAQ

    $20.35
    -0.09 (-0.44%)

    Market Cap: $5.35B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Sabra Healthcare REIT Inc (SBRA) Earnings: Report Dates and Results

    Updated Nov 2, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    FFO per share for Sabra Healthcare REIT (SBRA) was $1.54 for 2025. In the quarter ended Sep 30, 2026, Sabra Healthcare REIT reported EPS of $0.41, above the $0.39 estimate. It beat the EPS estimate in 4 of the last 8 quarters. Sabra Healthcare REIT is expected to report earnings on Feb 10, 2027.

    Earnings

    Performance (10Y)

    Beat Rate
    35%(14/40)
    Avg Surprise
    -24.64%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.18
    Range$0.16 - $0.22
    10 analysts
    Revenue Consensus
    $248.53M
    Range$214.23M - $273.60M
    12 analysts
    Reports Apr 27, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.16
    Range$0.16 - $0.16
    1 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.18-11.1%
    60d ago$0.20-20.0%
    30d ago$0.20-20.0%
    7d ago$0.20-20.0%
    Current$0.16
    Revenue Consensus
    $254.33M
    Range$241.13M - $272.94M
    6 analysts

    Next Report

    SBRA has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 63.6% above the $0.11 reported for the quarter ended Dec 31, 2025.

    SBRA Earnings Call

    The latest SBRA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, SBRA beat 14, missed 22 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $220.15M, up 38.3% from $159.21M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.41$0.39N/A+5.13%Beat+7.9%20 up, 1 downNov 2, 2026$220.15M
    Jun 30, 2026$0.40$0.38N/A+5.26%Beat+60.0%30 up, 1 downAug 3, 2026$203.40M
    Mar 31, 2026$0.16$0.16$0.14 - $0.180.00%In line-5.9%31 up, 0 downApr 29, 2026$193.29M
    Dec 31, 2025$0.11$0.17$0.15 - $0.17-35.29%Miss-35.0%20 up, 1 downFeb 12, 2026$295.51M
    Sep 30, 2025$0.38$0.37N/A+2.70%Beat+153.3%3N/ANov 5, 2025$159.21M
    Jun 30, 2025$0.25$0.17$0.17 - $0.17+47.06%Beat+56.3%11 up, 0 downAug 4, 2025$176.31M
    Mar 31, 2025$0.17$0.17$0.17 - $0.170.00%In line+30.8%11 up, 0 downMay 5, 2025$156.48M
    Dec 31, 2024$0.17$0.17$0.17 - $0.17-0.47%Miss+141.7%20 up, 0 downFeb 19, 2025$271.43M
    Sep 30, 2024$0.15$0.16$0.13 - $0.17-6.25%Miss+7.1%61 up, 0 downOct 31, 2024$148.53M
    Jun 30, 2024$0.16$0.15$0.14 - $0.16+6.67%Beat+77.8%70 up, 0 downAug 7, 2024$146.91M
    Mar 31, 2024$0.13$0.14$0.13 - $0.14-7.14%Miss+44.4%70 up, 0 downMay 8, 2024$139.10M
    Dec 31, 2023$0.07$0.13$0.13 - $0.15-46.15%MissN/A70 up, 0 downFeb 27, 2024$248.45M
    Sep 30, 2023$0.14$0.13$0.12 - $0.14+7.69%Beat+180.0%80 up, 0 downNov 6, 2023$135.70M
    Jun 30, 2023$0.09$0.09$0.08 - $0.120.00%In line-35.7%70 up, 0 downAug 7, 2023$132.84M
    Mar 31, 2023$0.09$0.20N/A-55.00%Miss-50.0%41 up, 0 downMay 3, 2023$131.58M
    Dec 31, 2022-$0.37$0.13$0.09 - $0.18-384.62%MissN/A60 up, 1 downFeb 21, 2023$137.09M
    Sep 30, 2022$0.05$0.26N/A-80.77%Miss0.0%60 up, 0 downNov 7, 2022$114.55M
    Jun 30, 2022$0.14$0.18$0.14 - $0.18-22.22%Miss-12.5%60 up, 0 downAug 3, 2022$128.26M
    Mar 31, 2022$0.18$0.16$0.11 - $0.21+12.50%Beat+12.5%80 up, 0 downMay 4, 2022$137.93M
    Dec 31, 2021-$0.11$0.14$0.01 - $0.26-178.57%Miss-161.1%8N/AFeb 22, 2022$52.66M
    Sep 30, 2021$0.05$0.17$0.01 - $0.18-70.59%Miss-64.3%7N/ANov 3, 2021$103.71M
    Jun 30, 2021$0.16$0.14$0.14 - $0.18+14.29%Beat-23.8%5N/AAug 4, 2021$128.58M
    Mar 31, 2021$0.16$0.19N/A-15.79%Miss-20.0%4N/AMay 5, 2021$151.71M
    Dec 31, 2020$0.18$0.17$0.13 - $0.22+5.88%Beat-10.0%8N/AFeb 22, 2021$214.06M
    Sep 30, 2020$0.14$0.18$0.09 - $0.19-22.22%Miss-36.4%6N/ANov 5, 2020$118.32M
    Jun 30, 2020$0.21$0.12$0.10 - $0.21+75.00%Beat-54.3%4N/AAug 5, 2020$128.17M
    Mar 31, 2020$0.20$0.21$0.19 - $0.21-4.76%Miss+11.1%6N/AMay 6, 2020$125.90M
    Dec 31, 2019$0.20$0.20$0.14 - $0.250.00%In lineN/A7N/AFeb 24, 2020$182.67M
    Sep 30, 2019$0.22$0.18$0.14 - $0.21+22.22%Beat+10.0%7N/AOct 30, 2019$120.15M
    Jun 30, 2019$0.46$0.24N/A+91.67%Beat+58.6%1N/AAug 7, 2019$209.25M
    Mar 31, 2019$0.18$0.22N/A-18.18%Miss-47.1%1N/AMay 8, 2019$135.42M
    Dec 31, 2018-$0.09$0.13$0.13 - $0.13-169.23%Miss-115.8%1N/AFeb 24, 2019N/A
    Sep 30, 2018$0.20$0.34$0.31 - $0.35-41.18%Miss+66.7%4N/ANov 5, 2018$153.25M
    Jun 30, 2018$0.29$0.51N/A-43.14%Miss+7.4%2N/AAug 8, 2018$309.31M
    Mar 31, 2018$0.34$0.49$0.26 - $0.54-30.61%Miss+25.9%3N/AMay 9, 2018$168.53M
    Dec 31, 2017$0.57$0.46$0.15 - $0.48+23.91%Beat+83.9%4N/AFeb 21, 2018$73.47M
    Sep 30, 2017$0.12$0.29-$0.57 - $0.32-58.62%Miss-63.6%4N/ANov 1, 2017$111.87M
    Jun 30, 2017$0.27$0.26$0.24 - $0.44+3.85%Beat-50.0%5N/AAug 2, 2017$69.71M
    Mar 31, 2017$0.27$0.32N/A-15.63%MissN/AN/AN/AMay 8, 2017$64.78M
    Dec 31, 2016$0.31$0.32N/A-3.13%Miss-8.8%N/AN/AFeb 22, 2017$61.00M
    Last 40 quarters

    Annual FFO

    FFO per share was $1.54 for 2025, up 6.9% from $1.44 in 2024. It was $2.33 for 2016, the oldest of the 10 years shown.

    Fiscal yearFFO per shareChange
    2025$1.54+6.9%
    2024$1.44-2.0%
    2023$1.47-6.4%
    2022$1.57-11.8%
    2021$1.78-5.8%
    2020$1.89-17.5%
    2019$2.29+14.5%
    2018$2.00-16.3%
    2017$2.39+2.6%
    2016$2.33N/A

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.91, up 49.4% from the year before. It was $0.90 for the year ended Dec 31, 2016, the oldest of the 9 fiscal years below with reported EPS.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.91+49.4%
    Dec 31, 2024$0.61+56.2%
    Dec 31, 2023$0.39N/A
    Dec 31, 2022Not reportedN/A
    Dec 31, 2021$0.26-64.4%
    Dec 31, 2020$0.73-31.1%
    Dec 31, 2019$1.06+43.2%
    Dec 31, 2018$0.74-39.8%
    Dec 31, 2017$1.23+36.7%
    Dec 31, 2016$0.90N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,700 words across 15 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,72615
    2026Q2Jun 30, 20268,38517
    2026Q1Mar 31, 20267,41717
    2025Q4Dec 31, 20256,04516
    2025Q3Sep 30, 20254,25412
    2025Q2Jun 30, 20256,10614
    2025Q1Mar 31, 20255,22114
    2024Q4Dec 31, 20246,84216

    2026Q3 Earnings Call

    Opening remarks

    Lukas Michael Hartwich EVP of Finance Thank you, and good morning. Before we begin, I want to remind you that we will be making forward-looking statements in our comments and in response to your questions concerning our expectations regarding future financial position and results of operations, including our earnings guidance for 2026, and our expectations regarding our tenants and operators, as well as our acquisition, disposition, and investment plans. These forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the risks listed in our Form 10-K for the year ended December 31, 2025, as well as in our earnings press release included as Exhibit 99.1 to the Form 8-K we furnished to the SEC yesterday. We undertake no obligation to update our forward-looking statements to reflect subsequent events or circumstances, and you should not assume later in the quarter that the comments we make today are still valid. In addition, references will be made during this call to non-GAAP financial results. Investors are encouraged to review these non-GAAP financial measures, as well as the explanation and reconciliation of these measures to the comparable GAAP results, included on the Financials page of the Investors section of our website at sabrahealth.com. Our Form 10-Q, earnings release, and supplement can also be accessed in the Investors section of our website. And with that, let me turn the call over to Richard K. Matros, CEO, President, and Chair of Sabra Health Care REIT.

    Richard K. Matros CEO, President, and Chair Thanks, Lukas, and thanks, everybody, for joining us this morning. Our same-store SHOP cash NOI margins were 34.9%, which is best in class. Our RevPAR growth was stellar again for the quarter, along with solid cash NOI growth and occupancy increases. We have closed on $750 million in investments to date, all of which is SHOP except for $100 million, which was skilled nursing. We have $425 million awarded and expect more to come before year-end. All of that, except for $24 million, is SHOP. Our skilled nursing and senior housing triple-net rent coverage continues to get better. As we continue to move forward toward 40% SHOP exposure, going to 50% by year-end 2027, our senior housing portfolio will outweigh our skilled portfolio for the first time as that exposure drifts closer to 40%. We see no barriers that would prevent this from continuing. That said, we believe it is important to have that diversity in the portfolio. As we have demonstrated, our skilled portfolio offers more earnings growth than the 2.5% escalators that we have seen historically. Our focus on optimizing rents was evident in our July announcement, and we are currently assessing other opportunities.

    Frequently Asked Questions About SBRA

    When is Sabra Healthcare REIT's next earnings date?

    Sabra Healthcare REIT's next earnings report is expected for Feb 10, 2027.

    Did SBRA beat earnings estimates last quarter?

    Yes. Sabra Healthcare REIT reported EPS of $0.41 for the quarter ended Sep 30, 2026, above the $0.39 estimate, a 5.13% surprise.

    What EPS do analysts expect from SBRA next quarter?

    The consensus EPS estimate for Sabra Healthcare REIT for the quarter ending Dec 31, 2026 is $0.18 from 10 analysts, with estimates from $0.16 to $0.22.

    How often does SBRA beat earnings estimates?

    Sabra Healthcare REIT beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +3.05%.